Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Nephros Appoints Alisa Lask to its Board of Directors | ||
By: Nasdaq / GlobeNewswire - 11 Feb 2019 | Back to overview list |
|
SOUTH ORANGE, NJ, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced the appointment of Alisa Lask to its Board of Directors. Additionally, Moshe Pinto has resigned from the Nephros Board of Directors to focus his activities on the Board of Directors of Specialty Renal Products, Inc., Nephros’ majority-owned subsidiary developing a second generation hemodiafiltration device. About Nephros, Inc. Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, known as ultrafilters. Nephros ultrafilters are primarily used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas), viruses, and endotoxins from water, providing barriers that assist in improving infection control in showers, sinks, and ice machines. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and the patients. For more information about Nephros, please visit the company’s website at www.nephros.com. Forward-Looking Statements This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’s ability to increase penetration into its current markets, its ability to launch products into new markets, whether it will acquire new products or businesses, and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including uncertainty in clinical outcomes, potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, dependence on third party manufacturers and researchers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros’s reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2017. Nephros does not undertake any responsibility to update the forward-looking statements in this release. CONTACT: Contact: Investor Relations Contact: Andy Astor COO/CFO, Nephros andy@nephros.com (201) 345-0824 |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |